Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature

Nick Thomson¹ & Matthew Ulrickson²

¹Department of Internal Medicine, University of Arizona College of Medicine Phoenix, Phoenix, Arizona, USA
²Department of Hematology/Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA

Introduction

Atypical hemolytic uremic syndrome (aHUS) is caused by a disorder in complement regulation, which leads to leukocyte and platelet activation, thrombotic microangiopathy, and subsequent end-organ damage [1]. It is distinguished from typical hemolytic uremic syndrome (HUS) in that it lacks coexisting disease such as Shiga-toxin-producing Escherichia coli (STEC) and Streptococcus pneumoniae [2]. Common causes of atypical HUS include complement gene mutations, which the majority of patients who suffer from aHUS carry, while antibodies to complement factor H have also been implicated in a smaller subset of patients [3, 4]. Classic laboratory findings include hemolytic anemia, thrombocytopenia, and acute kidney injury [5]. Atypical HUS is distinguished from thrombotic thrombocytopenic purpura (TTP) by its lack of reduction in activity of ADAMTS13. Untreated aHUS is associated with permanent renal dysfunction, high recurrence rate, and high mortality [6]. Historically, prognosis was poor: studies showed that 33–40% of patients progressed to ESRD or death during the first clinical manifestation [3]. Within 1 year of diagnosis, up to 65% of patients managed with plasma exchange (PEX) suffered permanent renal damage, progressed to ESRD, or died [7]. The elucidation of the pathogenesis from uncontrolled activation of the alternative complement pathway, resulting in formation of the membrane attack complex (MAC) C5b-9 [8] has ultimately led to treatment with eculizumab, a monoclonal IgG antibody that binds to C5 and prevents subsequent formation of terminal complement [9]. Benefit from eculizumab was initially demonstrated in patients with paroxysmal nocturnal hemoglobinuria (PNH) [10] and subsequently in the treatment of aHUS [11, 12]. Dosing of eculizumab in the treatment of aHUS is 900 mg IV weekly for induction for 4 weeks followed by maintenance at 1200 mg IV every 2 weeks [13]. These recommended doses were extrapolated from the data in PNH, as the frequency of aHUS did not allow more specific investigation prior to approval of the agent. Dosing that adequately controls complement activation is necessary to achieve optimal outcomes for patients.
Case Presentation

A 26-year-old previously healthy Hispanic male presented with 2 days of epigastric abdominal pain with associated nausea, vomiting, and gross hematuria. He was found to have acute kidney injury (Cr 4.07 mg/dL), thrombocytopenia (PLTs 70K/mm³), and microangiopathic hemolytic anemia as evidenced by schistocytes seen on a peripheral blood smear. Treatment for presumed TTP was initiated at an outside institution with high-dose intravenous steroids and plasmapheresis. In spite of this treatment, his renal function continued to decline with creatinine increasing to a peak of 9 mg/dL. Hemodialysis was initiated on day 4 of presentation. His ADAMTS13 activity was found to be within normal limits (124%). After transfer, quantitative assessment of complement revealed levels within normal limits, including C3 and C4 at 97 and 39 mg/dL, respectively.

Pneumococcal HUS, HIV, and drug-related thrombotic microangiopathy were excluded in our patient’s workup. Subsequent quantitative complement assessment did reveal abnormally low levels, including C3 and Complement Factor B of 68 and 16 mg/dL, respectively. The patient was found to have very low CH50 of <10 units/mL. A diagnosis of aHUS was made, plasmapheresis was discontinued, and eculizumab therapy was initiated shortly after immunization against *N. Meningitidis*. Ceftriaxone prophylaxis was administered for 2 weeks.

The patient was started on induction eculizumab at 900 mg IV weekly for 4 weeks and responded well with improvement in platelet count and renal function. He was transitioned to every-other-week maintenance eculizumab and hemodialysis was discontinued. However, approximately 6 weeks after switching to maintenance dosing, the patient developed recurrent abdominal pain, which he described as identical to his pain at initial presentation. Coincident with this, his platelet count declined, his LDH increased, and his renal function worsened (Fig. 1). These and other parameters, including haptoglobin, eGFR, and urinalysis, which were regularly monitored for response, demonstrated clinical decline. Due to these signs and symptoms, an increase was made to the dosing regimen of eculizumab rather than the addition of plasma therapy, which had proven ineffective for the patient at the time of diagnosis. He was transitioned back to weekly dosing of 900 mg IV, which once again led to improvement in symptoms and organ function.

The patient has remained clinically stable for 6 months on weekly dosing of 900 mg IV at the time of writing of this article. He has not experienced side effects from therapy such as headache, hypertension, diarrhea, or leukopenia, as are most commonly experienced [13]; nor has he demonstrated signs or symptoms of meningitis in spite of the increased dosing regimen over this time period.

Discussion

It is imperative to note that approximately 50% of patients with aHUS present with normal complement levels and therefore, normal levels cannot be used to exclude the diagnosis [3]. Workup for aHUS should include functional assessment of complement via the terminal hemolytic complement (THC or CH50), which may be significantly low due to a genetic deficiency of one or more complement proteins. Genetic assessment can also be utilized for diagnostic purposes, however, diagnosis of aHUS can still be made in spite of normal genetic testing because all contributing genetic factors are not yet known.

Therapy with eculizumab has been associated with an increased risk of meningococcal infections (and other encapsulated organisms) due to the inhibitory effect on terminal complement. Vaccination against *N. Meningitidis* preferentially occurs 2 weeks prior to eculizumab initiation; however, given our patient’s clinical acuity, therapy was started immediately after vaccine administration given that the risk of treatment delay outweighed the risk of developing a meningococcal infection. Prophylactic antibiotics against *N. Meningitidis* were administered for 2 weeks. With regard to duration of therapy, most patients with aHUS are treated with eculizumab indefinitely; however, some patients are able to be successfully weaned off treatment [14]. One retrospective series reports a median exposure of 3 years [15].

Eculizumab administration by intravenous route requires that the medication be permitted to achieve room temperature prior to administration. It is infused over 35 min in adults, and 1–4 h in pediatric patients. It is not to be administered as a bolus injection or IV push. A maximum duration of 2 h of infusion in adults should not be exceeded. Should infusion reactions occur, infusion rates should be decreased or discontinued. Patients should be monitored for signs and symptoms of infusion reaction for at least 1 h after the completion of an infusion. Adequate supportive therapy is indicated throughout treatment, including maintenance of fluid balance, adequate blood pressure control, and electrolyte monitoring and replacement [13].

Due to the low prevalence of aHUS, the recommended dosing of eculizumab was based largely on the experience in treating PNH. The number of patients tested in the initial treatment that led to FDA approval was 87 [16]. For this reason, the standard dosing strategy may not be optimal for all patients as seen in the case presented. Examples of under-dosing exist in the PNH literature.
also, where patients required dose adjustment due to lack of response [17, 18]. To date, there are no reports in the literature that describe the need for dose titration of eculizumab in aHUS, though other cases of apparent under-dosing have been observed during the transition to maintenance therapy (personal communication).

Several markers have been investigated that may help to evaluate efficacy of eculizumab, though none are yet proven to be reliable for dose-modification. This remains best directed by clinical evaluation of the patient, as in our case. Potential markers that have been described include urine C5a and sC5b-9, which decreased in studies immediately after first dose of eculizumab therapy [19]. However, a significant fraction of patients with aHUS have been found to have normal circulating levels of C3, sC5b-9, and C5A in serum, making these markers less clinically reliable [20]. Other markers that decreased upon treatment include thrombomodulin (TM), a cell surface glycoprotein which is suggestive of decreased endothelial damage [19] and F1+2 (a prothrombin fragment) as well as D-Dimer, indicating that eculizumab-induced terminal complement blockade downregulates the coagulation cascade which may be useful for monitoring [21].

CH50 assays to monitor patient response in those treated with eculizumab have been proposed in the setting of both PNH and aHUS [22, 23]. However, other studies have demonstrated CH50 to poorly correlate with patient response, and those authors propose following endothelial complement deposition assays [20]. A contributor to the challenge in identifying a biomarker of response in aHUS patients is that complement dysregulation continues even in treated patients via chronic activation of the alternative complement pathway [21]. Thus, eculizumab, at therapeutic levels, can reduce ongoing endothelial damage and renal injury from terminal complement in spite of ongoing chronic alternative complement pathway activation.

Both CH50 and circulating free eculizumab levels are the most promising markers of response in patients treated with eculizumab [22] and one group has suggested individualized dosing schedules based on eculizumab levels [24], but this strategy requires further validation.

Conclusions

There are currently no clinically validated assays available that help to guide dose adjustment of eculizumab in patients with aHUS and instead, decisions must be made based on ongoing clinical evaluation of the patient. As demonstrated in the case of our patient, it may be necessary to increase the dose of eculizumab if clinical targets are not being met or initial response is lost after transition to maintenance schedule. Further pharmacodynamic
studies of eculizumab, as well as the development of a dependable biomarker assay are needed to elucidate routine methods for determining necessary dose adjustments in patients with aHUS who experience inadequate control of their disease.

**Conflict of Interest**

None declared.

**References**

1. Loirat, C., and V. Fremeaux-Bacchi. 2011. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 6:60.
2. Loirat, C., F. Fakhouri, G. Ariceta, N. Besbas, M. Bitzan, A. Bjerre, et al. 2016. An international concensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrol. 31:15–39.
3. Noris, M., J. Capriolo, E. Bresin, C. Mossali, G. Pianetti, S. Gamba, et al. 2010. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5:1844–1859.
4. Kavanagh, D., A. Richards, V. Fremeaux-Bacchi, M. Noris, T. Goodship, G. Remuzzi, et al. 2007. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2:591–596.
5. Noris, M., and G. Remuzzi. 2005. Hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16:1035–1050.
6. Moake, J. L. 2002. Thrombotic microangiopathies. N. Engl. J. Med. 347:589–600.
7. Capriolo, J., M. Noris, S. Brioschi, G. Pianetti, F. Castelletti, P. Bettinaglio, et al. 2006. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279.
8. Noris, M., and G. Remuzzi. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361:1676–1687.
9. Thomas, T. C., S. A. Rollins, R. P. Rother, M. A. Giannoni, S. L. Hartman, E. A. Elliott, et al. 1996. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33:1389–1401.
10. Brodsky, R. A., N. S. Young, E. Antonioli, A. M. Risitano, H. Schrezenmeier, J. Schubert, et al. 2008. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840–1847.
11. Gruppo, R. A., and R. P. Rother. 2009. Eculizumab for congenital atypical hemolytic uremic syndrome. N. Engl. J. Med. 360:544–546.
12. Nürnberg, J., T. Phillipp, O. Witzke, A. Opazo Saez, U. Vester, H. A. Baba, et al. 2009. Eculizumab for atypical hemolytic uremic syndrome. N. Engl. J. Med. 360:542–544.
13. Highlights of prescribing information. (Eculizumab). Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf (accessed 15 February 2016).
14. Legendre, C. M., C. Licht, P. Muus, L. A. Greenbaum, S. Babu, C. Bedrosian, et al. 2013. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368:2169–2181.
15. Mallett, A., P. Hughes, J. Szer, A. Tuckfield, C. Van Eps, S. B. Campbell, et al. 2015. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern. Med. J. 45:1054–1065.
16. Hillmen, P., N. S. Young, J. Schubert, R. A. Brodsky, G. Socie, P. Muus, et al. 2006. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355:1233–1243.
17. DeZern, A., D. Dorr, and R. Brodsky. 2013. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur. J. Haematol. 90:16–24.
18. Kelly, R., S. Richards, P. Hillmen, and A. Hill. 2009. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther. Clin. Risk Manag. 5:911–921.
19. Noris, M., F. Mescia, and G. Remuzzi. 2012. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8:622–633.
20. Noris, M., M. Galbusera, S. Gastoldi, P. Macor, F. Banterla, E. Bresin, et al. 2014. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:1715–1726.
21. Cofield, R., A. Kukreja, K. Bedard, Y. Yan, A. P. Mickle, M. Ogawa, et al. 2015. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125:3253–3262.
22. Peffault de Latour, R., V. Fremeaux-Bacchi, R. Porcher, A. Xhaard, J. Rosain, D. C. Castaneda, et al. 2015. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 125:773–783.
23. Cugno, M., R. Gualtierotti, I. Possenti, S. Testa, F. Tel, S. Griffini, et al. 2014. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J. Thromb. Haemost. 12:1440–1448.
24. Gatault P., G. Brachet, D. Ternant, D. Degenne, G. Recipon, C. Barbet, et al. 2015. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs 7:1205–1211.